Clinical Cardiology Alert – February 1, 2006
February 1, 2006
View Archives Issues
-
Pharmacology Watch
Letrozole for Postmenopausal Women with Breast Cancer; Do Antidepressants Increase Risk of Suicide?; Can Viagra Improve Heart Function?; Can Tamoxifen Increase Your Height?; A Dramatic Increase of Clostridium difficile; FDA Actions -
Clinical Briefs in Primary Care supplement
-
Stroke Post Myocardial Infarction
The relationship of stroke to myocardial infarction (MI) remains controversial. Thus, Witt and colleagues from the Mayo Clinic in Rochester, MN, evaluated a community-based cohort of 2160 patients with acute MI hospitalized between 1979 and 1998 to determine the incidence of stroke after MI and its influence on survival. Ischemic and hemorrhagic strokes were included. Follow-up averaged 5.6 years (range, 0-22 years). -
Anticoagulation for Atrial Fibrillation in Acute Myocardial Infarction
In daily clinical practice, OAC was only given to a minority (30%) of AMI patients with AF, despite the fact that OAC was associated with a 29% relative and 7% absolute reduction in 1-year mortality after adjustment for confounding variables. The results emphasize the importance of OAC treatment for AF after AMI. -
Fenofibrate Therapy in Diabetics
Fenofibrate did not significantly reduce the risk of the primary outcome of coronary death or non-fatal MI. It did reduce total cardiovascular events, mainly due to fewer non-fatal myocardial infarctions and revascularizations. -
Prophylactic Amiodarone After Heart Surgery
Oral amiodarone prophylaxis of atrial tachyarrhythmias after cardiac surgery is effective and well tolerated. -
Arrhythmogenic Right Ventricular Dysplasia
There is a wide variation in presentation and course of ARVD patients, which can likely be explained by the genetic heterogeneity of the disease. -
A Population Study of Acute Vascular Events
The high rates of acute vascular events outside the coronary arterial territory and the steep rise in event rates with age in all territories have implications for prevention strategies, clinical trial design, and the targeting of funds for service provision and research.